Ovid Therapeutics Outlines 2019 Clinical and Business

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
41
Ovid Therapeutics Outlines 2019 Clinical and Business Priorities

-- OV101 in Angelman syndrome : Pivotal Phase 3 NEPTUNE trial expected to begin in second half 2019 --

-- OV101 in Fragile X syndrome : Phase 2 ROCKET clinical trial results in adolescents and young adults expected in second half 2019 --                -- OV935/TAK-935 in rare developmental and epileptic encephalopathies : Recent results from Phase 1b/2a trial in adults expected to bolster current clinical development program in children; enrollment in ARCADE trial in CDKL5 deficiency disorder and Duplication 15 syndrome expected to complete in second half 2019 --

NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today outlined key clinical and business priorities for 2019.

“2018 was a year of exciting clinical achievement and disciplined corporate execution, as we made important steps forward in two rare disorders with significant unmet medical needs: Angelman syndrome and rare developmental epilepsies,” said Jeremy Levin, DPhil, MB, BChir, chairman and chief executive officer of Ovid Therapeutics. “Two events announced in December 2018 created a very solid foundation for progress in 2019 and beyond. Specifically, following our End-of-Phase 2 meeting with the FDA, we have a clear and realistic development path for our Angelman syndrome program, paving the way for the first potential treatment for a disorder with no approved medicines anywhere in the world. Similarly, we are very encouraged about the potential of OV935 to treat rare developmental and epileptic encephalopathies (DEE). Our pre-clinical research and Phase 1b/2a results suggest OV935 may have anti-ictal as well as anti-epileptogenic properties, which could represent a new medical option to treat these devastating epilepsies.

“In 2019, the anticipated start of our pivotal Phase 3 trial in Angelman syndrome, results from our Phase 2 ROCKET trial for OV101 in Fragile X syndrome, and the continued progress of our Phase 2 trials from our broad development program in DEE for OV935 each has the potential to redefine the way patients and families are living with these rare disorders.”

2018 Highlights and Anticipated 2019 Clinical and Regulatory Milestones

OV101 for Angelman Syndrome A novel delta (δ)-selective GABA A receptor agonist entering Phase 3 clinical development.

Based on results announced in 2018 for the Phase 2 STARS clinical trial and discussion with the U.S. Food and Drug Administration (FDA) during an End-of-Phase 2 meeting, Ovid announced plans on December 6, 2018 to move ahead with a single pivotal Phase 3 trial of OV101 in pediatric patients with Angelman syndrome, called NEPTUNE, pending FDA concurrence on the study protocol and supporting framework and materials. If positive, NEPTUNE is intended to support a New Drug Application for OV101.

In 2019, Ovid expects to achieve the following key milestones for its Angelman syndrome program:

  • Enroll first patient in the ELARA trial, an open-label extension study, in the first quarter of 2019.
  • Submit Phase 2 STARS clinical results for publication in a peer-reviewed medical journal.
  • Finalize protocol and operational plans for Phase 3 NEPTUNE trial and submit to FDA in the first half of 2019.
  • Initiate enrollment for Phase 3 NEPTUNE trial in the second half of 2019.
  • Engage with European Medicines Agency (EMA) on OV101 clinical development plans.

OV101 for Fragile X Syndrome In July 2018, Ovid initiated the Phase 2 ROCKET clinical trial, a randomized, double-blind, parallel-group trial to evaluate the safety, tolerability and efficacy of OV101 over 12 weeks in approximately 30 males with Fragile X syndrome aged 13 to 22 years. The SKY ROCKET trial was initiated in the third quarter of 2018 and is an observational study designed to provide additional data on the key endpoints being explored in the ROCKET trial. It is also designed to provide comparative data with the current standard of care. SKY ROCKET will enroll up to 30 males with Fragile X syndrome ages 5 to 30 years.

In 2019, Ovid expects to achieve the following key milestones for OV101’s Fragile X syndrome program:

  • Complete enrollment in Phase 2 ROCKET trial; announce data in second half 2019.
  • Complete enrollment in Phase 2 SKY ROCKET; announce data in second half 2019.

OV935 for Rare Developmental and Epileptic Encephalopathies (DEE) A potent, highly-selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H) being investigated as a novel approach to treating epilepsy. OV935 is being developed in the context of a unique collaboration with Takeda Pharmaceutical Company Limited. The companies share 50 percent of all development expenses and potential future revenues.

In a press release issued December 17, 2018, Ovid announced results from the Phase 1b/2a clinical trial of OV935 in 18 adults with rare DEE who had not been successfully treated with currently available treatment regimens. The trial achieved its primary endpoint of safety and tolerability, showing OV935 to be generally well tolerated. Exploratory efficacy analysis of OV935 showed progressive reduction over time in seizure frequency that was correlated with decreases in plasma 24-hydroxycholesterol (24HC) levels in adults across multiple DEE.

Ovid expects to achieve the following key milestones in 2019 for the OV935 development program:

  • Submit Phase 1b/2a clinical trial results for peer-review presentation at a scientific medical meeting in first half 2019.
  • Engage with EMA on OV935 clinical development plans.
  • Continue enrollment in ENDYMION open-label extension trial.
  • Complete enrollment in the second half of 2019 in the Phase 2 ARCADE trial, an open-label trial evaluating patients 2 to 17 years of age diagnosed with CDKL5 deficiency disorder and Duplication 15q syndrome.
  • Continue enrollment in Phase 2 ELEKTRA trial, a randomized, double-blind, placebo-controlled trial evaluating patients 2 to 17 years of age diagnosed with Dravet syndrome and Lennox-Gastaut syndrome.
  • Continue to evaluate the potential for plasma 24HC to be a biomarker.

Corporate

  • Continue to evaluate ex-U.S. licensing opportunities and potential partnerships that could accelerate the development of OV101 in Angelman and Fragile X syndromes and other potentially broader areas and could also provide potential non-dilutive forms of capital.

About Ovid Therapeutics Ovid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company using its BoldMedicine™ approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s lead investigational medicine, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935/TAK-935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare developmental and epileptic encephalopathies (DEE).

For more information on Ovid, please visit http://www.ovidrx.com/ .

Forward-Looking Statements This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding progress, timing, scope and results of clinical trials for Ovid’s product candidates, the reporting of clinical data regarding Ovid’s product candidates, the study of the role of 24-S-hydroxycholesterol (24HC) as a plasma-based biomarker, the publication of data in medical journals, the timing and outcome of future interactions with regulatory authorities, the approval or registration of Ovid’s product candidates by regulatory authorities, and the completion of any licensing or partnership agreements. You can identify forward-looking statements because they contain words such as “will,” “believes” and “expects.” Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the Securities and Exchange Commission under the caption “Risk Factors”. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts Investors: Lora Pike  Ovid Therapeutics Inc. lpike@ovidrx.com

Alex Gray Burns McClellan, Inc agray@burnsmc.com (212) 213-0006

Media: Jerica Pitts W2Opure jpitts @purecommunications.com (312) 858-3469

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 105

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 69

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 73

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 107

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 119

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 93

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

Mauna Kea Technologies Advances AI Integration in Endomicroscopy

Updated Category News Views 512

Mauna Kea Technologies and its Innovative AI Patent Mauna Kea Technologies, the proud inventor of Cellvizio®, a revolutionary platform that blends probe and needle-based confocal laser endomicroscopy (p/nCLE), has taken a significant step forward in the realm of artificial intelligence in medical diagnostic procedures. Recently, the company announced the granting of a...

Continue Reading
Hot Chili Limited Secures Approval for La Verde Expansion Drilling

Updated Category News Views 168

Hot Chili Limited's Significant Progress at La Verde Hot Chili Limited (OTCQX: HHLKF) has obtained key regulatory approval to enhance the drill coverage of its La Verde copper-gold discovery. This exciting development comes as the company aims to broaden exploration activities in an area strategically important to its operations. Understanding the La Verde Project The La...

Continue Reading
Investors on High Alert as Lithium Faces Growing Demand Challenges

Updated Category News Views 261

The Lithium Debate: Rising Tensions at COP30 At the recent climate discussions, the dialogue took an unexpected turn, raising eyebrows among investors in various clean-tech sectors. For the first time in thirty years of United Nations climate negotiations, serious concerns emerged regarding the social and environmental risks associated with lithium mining, which is...

Continue Reading
Edible Garden Expands USDA Organic Herb Line in New Markets

Updated Category News Views 71

Introducing Edible Garden's Organic Product Line Edible Garden AG Incorporated has been making headlines as a leader in controlled environment agriculture (CEA). Recently, they launched their USDA Organic herb product line at Green’s Natural Foods and The Extra Supermarket, which is a significant step in their mission to provide sustainably grown and organic produce....

Continue Reading
Growth Surge: The Value of $100 Investment in Riot Platforms

Updated Category News Views 148

Understanding the Rise of Riot Platforms Investors seeking substantial growth often look to companies like Riot Platforms (NASDAQ: RIOT), which has demonstrated impressive performance over the past five years. With a remarkable annualized return of 46.95%, Riot has outpaced the market by over 34.28%. This consistent growth contributes to a current market capitalization of...

Continue Reading